Paradigm Capital Management Inc. NY bought a new position in shares of Azenta, Inc. (NASDAQ:AZTA - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 40,900 shares of the company's stock, valued at approximately $1,044,000. Paradigm Capital Management Inc. NY owned about 0.09% of Azenta at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in AZTA. American Capital Management Inc. raised its stake in Azenta by 26.9% in the first quarter. American Capital Management Inc. now owns 1,296,024 shares of the company's stock valued at $27,385,000 after buying an additional 274,588 shares during the period. Bank of America Corp DE boosted its stake in shares of Azenta by 12.7% during the 1st quarter. Bank of America Corp DE now owns 468,046 shares of the company's stock worth $9,890,000 after acquiring an additional 52,757 shares during the period. Caxton Associates LLP increased its holdings in shares of Azenta by 152.5% during the 1st quarter. Caxton Associates LLP now owns 173,000 shares of the company's stock worth $3,655,000 after acquiring an additional 104,497 shares during the last quarter. Fifth Third Bancorp increased its holdings in shares of Azenta by 21,522.4% during the 1st quarter. Fifth Third Bancorp now owns 285,632 shares of the company's stock worth $6,035,000 after acquiring an additional 284,311 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Azenta in the 1st quarter valued at $1,509,000. Institutional investors own 99.08% of the company's stock.
Analysts Set New Price Targets
Several brokerages have issued reports on AZTA. Weiss Ratings downgraded shares of Azenta from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, August 11th. Needham & Company LLC increased their target price on Azenta from $33.00 to $37.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Azenta currently has an average rating of "Hold" and a consensus target price of $41.20.
Read Our Latest Stock Analysis on Azenta
Azenta Trading Down 12.1%
NASDAQ AZTA opened at $32.88 on Tuesday. Azenta, Inc. has a 12-month low of $15.93 and a 12-month high of $41.73. The company has a fifty day simple moving average of $28.12 and a 200 day simple moving average of $25.03. The company has a market cap of $1.44 billion, a P/E ratio of -11.91 and a beta of 1.37.
Azenta (NASDAQ:AZTA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.05. Azenta had a positive return on equity of 1.18% and a negative net margin of 20.63%.The business had revenue of $161.18 million during the quarter, compared to the consensus estimate of $149.31 million.
Azenta Company Profile
(
Free Report)
Azenta, Inc NASDAQ: AZTA is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.
In addition to hardware and informatics platforms for sample storage, Azenta's Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Azenta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Azenta wasn't on the list.
While Azenta currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
